The simultaneous delivery of both imatinib and curcumin via nanomaterials induces the release of CTSB from lysosomes, elicits LMP, and promotes cell death, therefore enhancing tumor cell sensitivity to imatinib (Acharya and Sahoo, 2016). Here, CTSB is linked to neoplasm.